RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients
Open Access
- 14 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0153796
Abstract
Hepatocellular carcinoma (HCC) is the second most common cause of cancer mortality worldwide. Most cases of HCC are associated with cirrhosis related to chronic hepatitis B virus or hepatitis C virus infections. Hypermethylation of promoter regions is the main epigenetic mechanism of gene silencing and has been involved in HCC development. The aim of this study was to determine whether aberrant methylation of RASSF1A and DOK1 gene promoters is associated with the progression of liver disease in Brazilian patients. Methylation levels were measured by pyrosequencing in 41 (20 HCC, 9 cirrhotic, and 12 non-cirrhotic) liver tissue samples. Mean rates of methylation in RASSF1A and DOK1 were 16.2% and 12.0% in non-cirrhotic, 26.1% and 19.6% in cirrhotic, and 59.1% and 56.0% in HCC tissues, respectively, showing a gradual increase according to the progression of the disease, with significantly higher levels in tumor tissues. In addition, hypermethylation of RASSF1A and DOK1 was found in the vast majority (88%) of the HCC cases. Interestingly, DOK1 methylation levels in HCC samples were significantly higher in the group of younger (p < 0.05). Our results reinforce the hypothesis that hypermethylation of RASSF1A and DOK1 contributes to hepatocarcinogenesis and is associated to clinicopathological characteristics. RASSF1A and DOK1 promoter hypermethylation may be a valuable biomarker for early diagnosis of HCC and a potential molecular target for epigenetic-based therapy.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR) (444071/2014-8)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/111.528/2013)
This publication has 26 references indexed in Scilit:
- Treatment of hepatocellular carcinoma: beyond international guidelinesLiver International, 2014
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesisJournal of Hepatology, 2011
- Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intakeJournal of Hepatology, 2011
- the Incidence and Risk Factors of Hepatocellular Carcinoma in Patients With Nonalcoholic SteatohepatitisHepatology, 2010
- Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomasCarcinogenesis, 2008
- DNA methylation in hepatocellular carcinomaWorld Journal of Gastroenterology, 2008
- Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factorsMutagenesis, 2007
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Hepatocellular carcinomaThe Lancet, 2003